Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 27881 trials
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
NCT04073290
Recruiting
Conditions Hepatic Encephalopathy, Cirrhosis, Liver...
Phase PHASE4
Enrollment 238
Locations 6 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or overt HE (OHE, grade II-IV). Liver cirrhosis is the most common cause of portal hypertension (PH). Patients who develop complications of PH, like variceal bleeding or refractory ascites, can benefit from a Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement. Unfortunately, post-TIPS HE is a common and often severe complication. Incidence of new onset or worsening of HE after TIPS is approximately 20-45%. Currently there is no strategy to prevent post-TIPS HE.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN] — Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
  • Drug: Placebo oral tablet — Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
  • Drug: Lactulose 667 milligram/milliliter Oral Solution — Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS

Primary Outcomes

  • post-TIPS Hepatic Encephalopathy (First 3 months after TIPS placement)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2020-01-21
Completion: 2026-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 238 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Universitaire Ziekenhuizen KU Leuven, Norgine
Principal Investigators:
  • Bart Takkenberg, MD, PhD (PRINCIPAL_INVESTIGATOR) - Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Information
Study Contact:
Koos de Wit, MD
0031-20-5668468
leverresearch@amc.uva.nl
Interventions
  • Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN] — Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
  • Drug: Placebo oral tablet — Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
  • Drug: Lactulose 667 milligram/milliliter Oral Solution — Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
Study Locations (6 sites)
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Academic Medical Centre, Amsterdam, Netherlands
University Medical Center Groningen, Groningen, Netherlands
Leiden University Medical Center, Leiden, Netherlands
Radboud University, Nijmegen, Netherlands
Erasmus Medical Center, Rotterdam, Netherlands
Eligibility Criteria
Inclusion Criteria: 1. Elective TIPS placement for refractory ascites or recurrent variceal bleeding: Recurrent tense ascites and one or more of the following criteria: i. Not responding to the maximal dose of diuretics (400 milligram spironolactone and 160 milligram furosemide). ii. Kidney insufficiency (Creatinine \> 135 umol/L) induced by diuretics. iii. Electrolyte disturbances (Sodium \< 125 mmol/L, Potassium \> 5.5 mmol/L) induced by diuretics. iv. Not tolerating higher dose of diuretics (e.g. because of subjective side effects like muscle cramps). Recurrent variceal bleeding, not responsive to treatment with endoscopic band ligation and beta-blockers, with a high risk of failure of endoscopic treatment: i. Patients with a variceal bleeding and Child-Pugh C (10-13 points) cirrhosis or ii. Patients with a variceal bleeding, Child-Pugh B and an active bleeding during endoscopy 2. Age ≥18 years 3. Confirmed liver cirrhosis as documented by liver biopsy, elastography (e.g. Fibroscan) or combination of usual radiological and biochemical criteria. 4. Signed informed consent Exclusion Criteria: 1. Any absolute contraindications for TIPS placement 2. Use of ciclosporin 3. Life-threatening variceal bleeding with emergency TIPS placement which can not be delayed 72 hours 4. Age \> 80 years 5. Non-cirrhotic portal hypertension 6. Portal vein thrombosis (main trunk) 7. HIV 8. Current or recent (\<3 months) use of rifaximin 9. Overt neurologic diseases such as Alzheimer's disease, Parkinson's disease 10. Pregnant or breastfeeding women 11. Patients refusing or unable to sign informed consent
Long-term Use of CCB and Breast Cancer Risk
NCT05972785
Active, positions filled
Conditions Hypertension,Essential, Breast Cancer
Phase Not Applicable
Enrollment 68500
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this retrospective observational study is to examine whether long-term calcium channel blocker (CCB) use is associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands . The main questions it aims to answer are: * Is long-term CCB use associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands and what is the dose-response nature of this association. * Does differences in the association between calcium channel blocker use and the development of breast cancer exist between Australian and Dutch women. The investigators will utilise data from the Australian Longitudinal Study on Women's Health (ALSWH) , 45 and Up Study and Rotterdam study.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Calcium channel blocker — Drugs with ATC code C08 will be categorised as calcium channel blockers.
  • Drug: Beta blocker — Drugs with ATC code C07 will be categorised as beta-blockers.
  • Drug: Diuretic — Drugs with ATC code C03 will be categorised as diuretics.
  • Drug: RAS — Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
  • Drug: Other AHT — Drugs with ATC code C02 will be categorised as other antihypertensives.
  • Drug: None AHT — None AHT

Primary Outcomes

  • Incident rate of invasive breast cancer (From cohort entry until the earliest date of one of the following: a diagnosis of invasive breast cancer, bilateral mastectomy (without breast cancer) or death, assessed up to 14 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Active, positions filled
Start Date: 2022-07-01
Completion: 2025-12
Eligibility
Age: 45 Years
Sex: FEMALE
Volunteers: Not specified
Enrollment: 68500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Curtin University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Drug: Calcium channel blocker — Drugs with ATC code C08 will be categorised as calcium channel blockers.
  • Drug: Beta blocker — Drugs with ATC code C07 will be categorised as beta-blockers.
  • Drug: Diuretic — Drugs with ATC code C03 will be categorised as diuretics.
  • Drug: RAS — Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
  • Drug: Other AHT — Drugs with ATC code C02 will be categorised as other antihypertensives.
Study Locations (1 sites)
Curtin university, Bentley, Western Australia 6102 Australia
Eligibility Criteria
Inclusion criteria: * Alive and still enrolled in the longitudinal cohort at the study entry (2004 to 2009) * Self-reported/diagnosed hypertension at study entry. Exclusion criteria: \+ A history of breast cancer.
Cf-PWV and TyG Index Study
NCT07589374
Not yet recruiting
Conditions Hypertension, Insulin Resistance Syndrom...
Phase Not Applicable
Enrollment 800
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease. Arterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk. At the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk. Another important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack. This study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods. No additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Carotid-femoral pulse wave velocity (cf-PWV) (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2026-07-01
Completion: 2028-07-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital de Base
Principal Investigators:
  • Jose F VILELA-MARTIN, PhD (PRINCIPAL_INVESTIGATOR) - Medicine School of São José do Rio Preto - SP - Brazil
Contact Information
Study Contact:
Marco A VIEIRA-da-SILVA, MSc
+55 (34) 99645-0117
vilelamartin@uol.com.br
Marco A de Almeida, MD
+55 (34) 99122-7594
telelo60@hotmail.com
Interventions
N/A
Study Locations (1 sites)
Medicine School of São José do Rio Preto, São José do Rio Preto, São Paulo 15090-000 Brazil
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years; * Both sexes; * Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation; * Not receiving antihypertensive medication at the time of assessment; * Availability of valid 24-hour ABPM data; * Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement; * Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index; * Ability and willingness to provide written informed consent (for prospectively recruited participants). Exclusion Criteria: * Use of antihypertensive medication at the time of evaluation; * Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements; * Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings; * Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements; * Presence of severe vascular disease or conditions affecting arterial waveform assessment; * Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis; * Pregnancy; * Refusal or inability to provide informed consent (for prospectively recruited participants).
Transscleral Selective Laser Trabeculoplasty Project
NCT06833060
Recruiting
Conditions Glaucoma,Open-Angle, Ocular Hypertension...
Phase NA
Enrollment 15
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty. Selective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors. Participants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Device Feasibility Masking/blinding: None

Interventions / Regimen

  • Device: Selective Laser Trabeculoplasty — Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty

Primary Outcomes

  • Frequency of Treatment-Related Adverse Events (From treatment to 30 days after)
  • Intensity of Treatment-Related Adverse Events (From treatment to 30 days after)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-19
Completion: 2025-11-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)
Collaborators: Quantel Medical
Principal Investigators:
  • Robert J. CASSON, MBBS (Hons), M.Biostat, DPhil (PRINCIPAL_INVESTIGATOR) - Royal Adelaide Hospital - Harley Eye Clinic
  • Mario de La TORRE, Prof. Dr. med. (STUDY_DIRECTOR) - Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)
Contact Information
Study Contact:
HILAIRE
473745745
rhilaire@quantelmedical.fr
Interventions
  • Device: Selective Laser Trabeculoplasty — Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty
Study Locations (1 sites)
Central Adelaide Local Health Network - Royal Adelaide Hospital, Adelaide, South Australia 5000 Australia
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older with OAG or OHT who are clinical candidates for routine SLT. * Mild to moderate OAG (defined as a mean deviation on the Humhprey Field Analyzer \[HFA\] \> -12.0 dB), resulting from primary open-angle glaucoma (POAG), or pseudoexfoliative glaucoma * OHT with open angles warranting IOP-lowering treatment * IOP ≥ 22mmHg or ≤ 35mmHg (after washout of any IOP-lowering medications) * Gonioscopically visible scleral spur for 360 degrees without indentation * Ability to visualize the peri-limbal sclera for 360 degrees (using a manual elevation of the lid) * Willing and able to participate in the 60 days +/-5 days study, to comply with the study procedures and to adhere to the follow-up schedule. * Participant capable of giving informed consent Exclusion Criteria: * Contraindications to conventional SLT (e.g. corneal abnormalities etc.) * Angle Closure Glaucoma * Congenital or developmental glaucoma * Secondary glaucoma included pigmentary glaucoma * Inability to conduct a reliable visual field (defined as fixation losses, false positives or false negatives greater than 33%) * Presence of any peripheral anterior synechiae (PAS) in the study eye * Any of the following visual field findings using the Humphrey visual field analyzer: * A HFA MD of worse than -12dB * Greater than or equal to 75% of points depressed below the 5% level and greater than or equal to 50% of points depressed below the 1% level on the PD plot * At least 50% of points (i.e., 2 or more) within the central 5 degrees with a sensitivity ≤0dB on the decibel plot * Points within the central 5 degrees of fixation with a sensitivity \<15 dB in both hemifields on the decibel plot * A visual field MD of worse than -12dB in the fellow eye * Cup: Disc Ratio more than 0.8 * More than two hypotensive medications required (combination drops are considered 2 medications) * Prior incisional or laser glaucoma surgery (including previous SLT) in the study eye * Prior corneal refractive surgery * Complicated cataract surgery ≤ 6 months prior to enrollment * Presence of visually significant cataract in the opinion of the investigator * Clinically significant disease in either eye as determined by the Investigator * Clinically significant amblyopia in either eye * Dense pigmentation or hemorrhage in the peri-limbal conjunctiva or anterior sclera, Pigmented Pinguecula and Pterigium * Women who are pregnant or may become pregnant during the course of the study * In the opinion of the investigator the participant might require other ocular surgery within the 12-months, unless for further reduction of their IOP. * Concurrent treatment with topical, nasal, inhaled or systemic steroids. * Uncontrolled systemic disease that could impact the ability of the participant to attend follow up visits as per the discretion of the investigator * Participation in another clinical study * Protected or vulnerable subjects (including but not limited to people with impaired intellectual functioning or mental illness, prisoners, terminally ill subjects, immunocompromised…) * People not able to read and understand the informed consent * People not able to read and understand English language
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07441278
Not yet recruiting
Conditions Pulmonary Hypertension Associated With I...
Phase PHASE2
Enrollment 177
Locations 0 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: NS-863 Low Dose — NS-863 is an orally administered drug.
  • Drug: NS-863 High Dose — NS-863 is an orally administered drug.
  • Other: Placebo — An orally administered NS-863 matching placebo.

Primary Outcomes

  • Change in pulmonary vascular resistance (PVR) at week 24 (From baseline to week 24)
  • Number of participants who experienced an adverse event (AE) up to approximately 24 weeks. (From baseline to week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Not yet recruiting
Start Date: 2026-07-01
Completion: 2028-12-14
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 177 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NS Pharma, Inc.
Collaborators: Nippon Shinyaku Co., Ltd.
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Drug: NS-863 Low Dose — NS-863 is an orally administered drug.
  • Drug: NS-863 High Dose — NS-863 is an orally administered drug.
  • Other: Placebo — An orally administered NS-863 matching placebo.
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria to be included in the trial: * Ability to provide written informed consent prior to participation in the trial, which includes the ability to comply with the requirements and restrictions listed in the informed consent form (ICF). Participants must be able to read, comprehend, and write at a level sufficient to complete trial-related materials * Adult male or female participants 18 to 80 years of age at the time the ICF is signed * A confirmed diagnosis of the following WHO Group 3 PH based on computed tomography imaging, which demonstrates the following evidence of ILD performed within 6 months prior to starting the Treatment Period: 1. ILD 2. CPFE: only allowed for participants with 15% or less emphysema, and the extent of the ILD must be greater than that of the emphysema. Participants may have any form of ILD (including IIP, IPF, and connective tissue disease) or CPFE * Results of the RHC within 35 days prior to Day 1 and meet all of the following criteria: 1. Participants receiving treatment with endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogs or prostacyclin receptor agonists, and/or calcium channel blockers are eligible only if on a stable dose for at least 90 days prior to RHC at baseline and throughout the Screening Period. For infusion prostacyclin analogs, dose adjustment based on the participant's body weight is allowed per medical practice. 2. Participants on chronic medication for underlying lung disease (ie, pirfenidone, etc.) are eligible only if on a stable dose for at least 90 days prior to RHC at baseline and throughout the Screening Period 3. Participants receiving treatment with oxygen therapy are eligible only if beginning for at least 30 days prior to RHC at baseline and throughout the Screening Period, and on a stable dose of oxygen for 30 minutes before RHC * Valid 6MWD * Women of childbearing potential (WOCBP) must have a negative pregnancy test before receiving the trial treatment and must agree to use contraception from the Screening Visit to at least 30 days after the last dose of the trial treatment. Male participants who could potentially cause pregnancy must agree to use contraception from the Screening Visit to at least 90 days after the last dose of the trial treatment to avoid pregnancy in their partners * Able to complete the scheduled visits and follow the instructions of the investigator Exclusion Criteria: Participants meeting any of the following criteria at the Screening Visit or baseline are ineligible to participate in this trial: * Have a diagnosis of PAH or PH for reasons other than WHO Group 3 PH-ILD as outlined in inclusion criterion 3 * Have evidence of clinically significant left-sided heart disease, as defined by: a. LVEF \<40% Notes: Participants with abnormal LV function attributable entirely to impaired LV filling due to the effects of RV overload (ie, RV hypertrophy and/or dilatation) will not be excluded * Receiving \> 6 L/min of oxygen supplementation by any mode of delivery at rest at baseline * Moderate or severe liver, renal, blood, or psychiatric disease: 1. Moderate and severe hepatic impairment by the Child-Pugh scoring system (Class B and Class C) 2. Moderate and severe renal impairment by estimated glomerular filtration rate (eGFR) \<60 mL/min/m2 3. Have mental disorders or other conditions that make it difficult to follow the protocol * History of clinically significant (per investigator's judgment) drug or alcohol abuse disorder within the last 6 months * Have mental disorders or other conditions that make it difficult to follow the protocol * History of calculus urinary * Have a deterioration of underlying disease or a lung or upper respiratory tract infection within 30 days prior to baseline * Initiation of pulmonary rehabilitation within 12 weeks prior to baseline * At the time of consent, more than 1 year has passed since registration for lung transplantation, or surgery related to PH treatment is scheduled * Have diseases or symptoms that limit evaluation of 6MWT (eg, peripheral vascular disease, musculoskeletal disorders, and obesity) * Participants who have participated in another clinical trial involving a drug or medical device, or have received treatment with an investigational product (including investigational formulations of marketed products), within 30 days prior to the Screening Visit or within 5 terminal phase half-lives of the investigational product, whichever is longer * Life expectancy is less than 6 months * Acute pulmonary embolism within 90 days prior to baseline * Current cigarette or e-cigarette smokers or those who have quit within the past 6 months, with a history of ≥20 pack-years smoking * Participants who are pregnant, breastfeeding, or planning to become pregnant during the time of trial participation * Use of dual platelet inhibitor therapy * Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with trial participation or trial treatment administration * Have a history of allergies to the excipients in the trial treatment * Known human immunodeficiency virus (HIV) positive status * Active hepatitis due to hepatitis B virus or hepatitis C virus * Use of any protocol prohibited medications. * Receipt of any live vaccine within 4 weeks prior to the first dose of trial treatment or expected need for live vaccination during trial participation, including at least 4 weeks after the last dose of trial treatment * The investigator has judged the participant as unwilling or unable to * comply with the protocol * Other concurrent disease and/or medical condition that, in the judgment of the investigator, may put the participant at risk or may influence the results of the trial or the participant's ability to complete the entire duration of the trial
Frailty, Physical Capacity and Lung Function in Postoperative Pulmonary Endarterectomy Patients
NCT06286891
Recruiting
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational and prospective study is to investigate changes in physical performance, lung function, respiratory and peripheral muscle strength in patients during the postoperative period following pulmonary endarterectomy (PET).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To investigate changes in physical performance measured by Six-Minute Walk Test. (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery.)
  • To investigate changes in physical performance measured by Short Physical Performance Battery (SPPB). (Baseline (one day before the surgery), after the surgery (the day immediately after ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after surgery.)
  • To investigate changes in physical performance by 1-minute sit-to-stand test (1-MSTST). (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate changes in peripheral muscle strength. (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate changes in respiratory muscle strength: (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate changes in lung function test measure by spirometry: (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate frailty by Clinical Frailty Scale (CFS) (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-29
Completion: 2026-11-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Principal Investigators:
  • Rafael M Ianotti, PT (PRINCIPAL_INVESTIGATOR) - Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Contact Information
Study Contact:
Rafael M Ianotti, PT
+55 11 26615319
rafael.ianotti@hc.fm.usp.br
Interventions
N/A
Study Locations (1 sites)
Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo 05403-000 Brazil
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Both genders * Elective pulmonary endarterectomy surgery * Absence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the preoperative period. Exclusion Criteria: * Reoperation for any reason * Presence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the postoperative period.
Effect of Heated Water-Based Versus Land-Based Exercise Training on Hemodynamic Variables, Functional Capacity and Quality of Life in Older Hypertensive
NCT07131748
Recruiting
Conditions Hypertension, Aging, Exercise
Phase NA
Enrollment 60
Locations 1 sites
Compensation compensation available
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

BACKGROUND: Physical exercise promotion is one of the main global goals of innumerous health and medical societies for preventing and managing noncommunicable chronic diseases (NCDs), being one of the main therapeutic for the patient with hypertension. Exercise in heated swimming pool has emerged as a potential alternative to physical exercise on the ground for the reduction of blood pressure (BP) of hypertensive patients, however, its effects on BP, as well as hemodynamic, metabolic, inflammatory and functional variables of older individuals with hypertension have not been investigated. PURPOSE: To evaluate the effects of heated water-based exercise (HEx) versus land-based exercise (LEx) on BP, arterial stiffness, endothelial function, metabolic, inflammatory and functional variables of older individuals with hypertension. METHODS: 60 older individuals (male and female) with hypertension (age \> 60 years) will be randomized in 2:2:1 ratio to HEx, LEx or control (CON) intervention. The feasibility and physiological adaptations (physical capacity, musculoskeletal and cardiovascular responses to stress, biological and biochemical markers associated with the pathophysiology of the disease and vascular adaptations) will be assessed before, after 12 weeks and after 24 weeks of follow-up. HEx and LEx training programs will be performed three times per week and will be performed for the firs 12 weeks of follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Physical Exercise Session in heated Swimming Pool - HEx — Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Physical Exercise Session in Land- LEx — Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Control Session Without Exercise- CON — Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.

Primary Outcomes

  • Blood pressure change (baseline, 3 month and 6 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-08-30
Eligibility
Age: 60 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidade Estadual Paulista Júlio de Mesquita Filho
Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Contact Information
Study Contact:
Awassi Y. Ngomane, Master
+5511985678113
awassiyn@gmail.com
Interventions
  • Other: Physical Exercise Session in heated Swimming Pool - HEx — Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Physical Exercise Session in Land- LEx — Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Control Session Without Exercise- CON — Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.
Study Locations (1 sites)
Universidade Estadual Paulista Julio de Mesquita Filho, Bauru, São Paulo 17033-360 Brazil
Eligibility Criteria
Inclusion Criteria: \- For the study population, the following will not be included in the study: * Smokers (avoiding acute effects of smoking on physiological measures); * Individuals with decompensated cardiovascular disease, thyroid dysfunction and / or inflammatory diseases; * Unable individuals to perform an exercise program or ergospirometric test due to physical or mental incapacity; * Individuals with hemodynamic and / or electrocardiographic changes during the ergospirometric test. * Only individuals older than 60 years, with a diagnosis of SAH for more than 6 months (stage 1 or 2), using antihypertensive medication (office BP less than 140/90 mmHg) and without medication change for at least 2 months. Exclusion Criteria: * For the study population, individuals who have less than 60% adherence to scheduled physical exercise sessions will be excluded during the study. * Individuals who change or discontinue their clinical and / or pharmacological treatment (with or without a prescription).
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523
Recruiting
Conditions Primary Open Angle Glaucoma
Phase NA
Enrollment 545
Locations 22 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Hydrus Microstent — Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
  • Procedure: Cataract surgery — Cataract surgery performed using standard anesthesia and phacoemulsification techniques
  • Device: Monofocal IOL — Commercially available monofocal intraocular lens as determined by the investigator

Primary Outcomes

  • Rate of occurrence of clinically significant device malposition associated with clinical sequelae (Day 0 operative, up to Month 24 postoperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-08-25
Completion: 2028-08
Eligibility
Age: 45 Years
Sex: ALL
Volunteers: false
Enrollment: 545 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alcon Research
Principal Investigators:
  • Clinical Project Lead, CDMA Surgical (STUDY_DIRECTOR) - Alcon Research
Contact Information
Study Contact:
Alcon Call Center
1-888-451-3937
alcon.medinfo@alcon.com
Interventions
  • Device: Hydrus Microstent — Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
  • Procedure: Cataract surgery — Cataract surgery performed using standard anesthesia and phacoemulsification techniques
  • Device: Monofocal IOL — Commercially available monofocal intraocular lens as determined by the investigator
Study Locations (22 sites)
Coastal Vision, Irvine, California 92618 United States
Sacramento Eye Consultants, Sacramento, California 95815 United States
Eye Center of Northern Colorado, Loveland, Colorado 80538 United States
Jones Eye Center PC, Sioux City, Iowa 51104 United States
Stiles Eyecare Excellence Cataracts and Glaucoma, Overland Park, Kansas 66213 United States
Visionary Eye Doctors, Rockville, Maryland 20852 United States
Fraser Eye Care Center, Fraser, Michigan 48026 United States
Twin Cities Eye Consultants, Coon Rapids, Minnesota 55433 United States
Midwest Vision Research Foundation, Chesterfield, Missouri 63017 United States
Moyes Eye Center, Kansas City, Missouri 64154 United States
Eligibility Criteria
Inclusion Criteria: * An operable, age-related cataract with best corrected visual acuity (BCVA) of 20/40 or worse; * Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications; * Optic nerve appearance characteristic of glaucoma; * Medicated IOP less than or equal to 31 millimeters mercury (mmHg); Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Closed angle forms of glaucoma; * Congenital or developmental glaucoma; * Secondary glaucoma; * Use of more than 4 ocular hypotensive medications; * Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery; * Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal; * Other protocol-defined exclusion criteria may apply.
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
NCT05321368
Recruiting
Conditions Hypertension, High Blood Pressure, Diabe...
Phase NA
Enrollment 425
Locations 3 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hypertension (BP ≥ 140/90 mm Hg) AND either type 2 diabetes or chronic kidney disease (CKD) across 16 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors and will be managed by the patients' primary care clinicians as usual; and (2) the "intervention arm" which will integrate HBPM telemonitoring, a CHW intervention and provider-level interventions into the usual clinical care to improve BP control and provide support for self-management of chronic conditions. The study pharmacist will conduct telehealth, use the Sphygmo app and the Pharmacist Patient Care Process to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: LINKED-HEARTS Program — The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

Primary Outcomes

  • Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-16
Completion: 2027-04-22
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 425 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Yvonne Commodore-Mensah, PhD, MSH, RN (PRINCIPAL_INVESTIGATOR) - JHU School Of Nursing
Contact Information
Study Contact:
Yvonne Commodore-Mensah, PhD, MSH
443-614-1519
ycommod1@jhu.edu
Interventions
  • Behavioral: LINKED-HEARTS Program — The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
Study Locations (3 sites)
Unity Health Care, Washington D.C., District of Columbia 20019 United States
Johns Hopkins Community Physicians, Baltimore, Maryland 21205 United States
Choptank Community Health Systems, Denton, Maryland 21629 United States
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age as of date of data extraction, 2. Self-identify as non-Hispanic white, non-Hispanic Black/African American and/or Hispanic, 3. Diagnosis of Hypertension (HTN) defined by International Classification of Diseases, Tenth code (ICD-10 code) and elevated systolic blood pressure (SBP) measure (≥140 mm Hg) on their most recent clinic visit. 4. Diagnosis of diabetes or chronic kidney disease (both defined by ICD-10 code), in addition to HTN 5. Receives primary medical care at one of the participating health systems 6. Have a Maryland and D.C. home address Exclusion Criteria: 1. Age \<18 years 2. Diagnosis of end-stage renal disease (ESRD) treated with dialysis 3. Serious medical condition which either limits life expectancy or requires active management (e.g., cancer) 4. Cognitive impairment or other condition preventing participation in the intervention 5. Planning to leave the practice or move out of the geographic area in 24 months 6. No longer consider the practice site their location for primary care 7. Unwillingness to provide informed consent
Real-World Study of PADN for the Treatment of PAH
NCT07039604
Recruiting
Conditions Pulmonary Hypertension, Hypertension, Pu...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Real-World Study of PADN for the Treatment of PAH

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China — PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.

Primary Outcomes

  • Clinical worsening (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-19
Completion: 2028-12-30
Eligibility
Age: No restriction
Sex: ALL
Volunteers: Not specified
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pulnovo Medical (Wuxi) Co., Ltd.
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Device: Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China — PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.
Study Locations (1 sites)
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with PAH and received PADN procedure since March 2024. 2. No contraindications to procedure. 3. Able to provide informed consent and authorize use of health/research data. 4. Compliant with treatment and follow-up requirements. Exclusion Criteria: None specified.
Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure
NCT06331208
Recruiting
Conditions Heart Failure, Pulmonary Hypertension, P...
Phase Not Applicable
Enrollment 230
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis. There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failure-related PVD. The mechanisms and non-invasive detection of HF-PVD are poorly understood and are the focus of the current grant application. Development of PVD is linked to insufficiently characterized metabolic factors that may be mediators of HF-PVD. Untargeted metabolomics is an emerging powerful platform for the discovery of pathways linked to diseases. Its specificity can be further enhanced using transpulmonary gradient sampling. Part A of the project aims to identify novel metabolites associated with the presence of PVD in patients with HF that can serve as biomarkers or targets and will provide biologic insights into PVD. Part C will assess the effects of reverting of metabolic alterations (identified in part A) by a drug/diet on pulmonary vasculature in experimental HF-related PVD. The "gold standard" for the detection of PVD is right heart catheterization, which is invasive and risky. Heart failure-related PVD is therefore often diagnosed late. There is a need for noninvasive tests that may help to detect PVD in early stages and can be done repeatedly. Recent advances in artificial intelligence (AI)-assisted automated quantitative analysis of lung texture from low-dose contrast-free high-resolution CT images allow to quantify lung water content, interstitial changes or vessel volume, and may provide clues for detection of heart failure-related PVD. Such an approach, not tested yet, will be utilized for the detection of HF-PVD (part B). Clinical and functional characteristics of lung circulation (exercise hemodynamics, diffusion capacity, perfusion) will be analyzed in relation to quantitative CT data.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: non-contrast chest CT — patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: supine bike exercise during right heart catheterisation — subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
  • Diagnostic Test: Lung ventilation/perfusion SPECT — subgroup of HF subjects will undergo ventilation/perfusion SPECT

Primary Outcomes

  • biomarker of pulmonary vasculopathy in HF (after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study))
  • CT characteristics of pulmonary vasculopathy in HF (after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study))
  • CT characteristics of presence of heart failure (after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-23
Completion: 2026-12-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Clinical and Experimental Medicine
Principal Investigators:
  • Vojtech Melenovsky (PRINCIPAL_INVESTIGATOR) - Institute for Clinical and Experimental Medicine
Contact Information
Study Contact:
Vojtech Melenovsky, MD, PhD
420 236055190
vome@ikem.cz
Interventions
  • Diagnostic Test: non-contrast chest CT — patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: supine bike exercise during right heart catheterisation — subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
  • Diagnostic Test: Lung ventilation/perfusion SPECT — subgroup of HF subjects will undergo ventilation/perfusion SPECT
Study Locations (1 sites)
Institute for Clinical and Experimental Medicine - IKEM, Prague, 140 21 Czechia
Eligibility Criteria
A) Inclusion Criteria HF group: * age\>18y * signed informed consent, * left ventricular (LV) ejection fraction \<50% * duration of HF\>6 months, * loop diuretic use, * clinical indication to right heart catheterisation Control group: * Age \>18years * Signed informed consent * Non-HF subjects referred to Institute for Clinical and Experimental Medicine (IKEM) in Prague for an invasive procedure (PFO closure, arrhythmia ablation, for subjects undergoing RHC) or non-invasive diagnostic evaluation (controls without invasive sampling) B) Exclusion Criteria: Heart Failure group: * Patients with hemodynamic instability requiring inotropic support * Severe renal insufficiency (estimated glomerular filtration rate \<0.6 ml/s) * Acute coronary syndrome * High cardiac output (cardiac index \>4 l/m2) * Known pulmonary hypertension of other type than II (type I, III, IV) * Active infection * Respiration insufficiency * Large pleural effusion * Severe intrinsic lung disease (treated chronic obstructive pulmonary disease (COPD) * asthma, known interstitial lung disease) Control group: * Pulmonary hypertension (RV systolic pressure estimate on screening \> 45 mmHg) * History of recent pulmonary embolism \< 1 year * Echocardiographic evidence of reduced function of right or left ventricle * Treated asthma/COPD, known intersticial lung disease * Significant exercise intolerance (NYHA \> II)
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
NCT07646860
Not yet recruiting
Conditions Pulmonary Arterial Hypertension
Phase PHASE2
Enrollment 6
Locations 0 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time and whether it lowers resistance in blood vessels in the lungs.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Sotatercept — Sotatercept subcutaneous injection every 3 weeks

Primary Outcomes

  • Number of Participants With One or More Adverse Events (Up to approximately 24 weeks)
  • Number of Participants Who Discontinue Study Intervention Due to an Adverse Event (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Concentration of Hemoglobin (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Hematocrit (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Reticulocyte Count (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Platelet Count (Up to approximately 24 weeks)
  • Blood Pressure (BP) (Up to approximately 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Not yet recruiting
Start Date: 2026-08-31
Completion: 2031-05-16
Eligibility
Age: 1 Year
Sex: ALL
Volunteers: false
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Merck Sharp & Dohme LLC
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Biological: Sotatercept — Sotatercept subcutaneous injection every 3 weeks
Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has pulmonary arterial hypertension (PAH, World Health Organization Group 1) confirmed by a prior right heart catheterization * Has idiopathic, heritable, drug- or toxin-induced PAH, connective tissue disease-associated PAH, repaired congenital heart disease-associated PAH, or PAH with coincidental shunt * Has PAH classified as World Health Organization Functional Class I, or symptomatic World Health Organization Functional Class II to IV * Has been receiving stable standard-of-care background therapy for PAH for at least 90 days * Is Japanese Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of left-sided heart disease * Has severe congenital or developmental abnormalities of the lung, thorax, and/or diaphragm * History of Eisenmenger syndrome, Potts shunt, or recent atrial septostomy within 180 days * Has unrepaired or residual cardiac shunt with Qp/Qs \>1.5 * Has pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, or overt signs of pulmonary capillary and/or venous involvement * PAH associated with portal hypertension * Known visceral arteriovenous malformations * History of full or partial pneumonectomy * Untreated more than mild obstructive sleep apnea * History of known pericardial constriction * Family history of sudden cardiac death or long QT syndrome * History of symptomatic coronary disease within 6 months or cerebrovascular accident within 3 months * Prior treatment with sotatercept or luspatercept
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
NCT06475781
Recruiting
Conditions Group 3 Pulmonary Hypertension
Phase PHASE2
Enrollment 126
Locations 9 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to see if mirivadelgat will work in patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs. Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being. Participants will: Take mirivadelgat or a placebo once a day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Receive phone calls every one or two weeks to check on how things are going

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Mirivadelgat — Selective aldehyde dehydrogenase 2 (ALDH2) activator
  • Drug: placebo — placebo

Primary Outcomes

  • Pulmonary Vascular Resistance (PVR) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-01
Completion: 2028-02
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.
Collaborators: QPS Holdings LLC
Principal Investigators:
  • Bassem Elmankabadi, MD (STUDY_DIRECTOR) - Foresee Pharmaceuticals
Contact Information
Study Contact:
Bassem Elmankabadi, MD
+1 562-310-8718
Bassem.elmankabadi@foreseepharma.com
Yisheng Lee, MD
408-823-4807
yisheng.lee@foreseepharma.com
Interventions
  • Drug: Mirivadelgat — Selective aldehyde dehydrogenase 2 (ALDH2) activator
  • Drug: placebo — placebo
Study Locations (9 sites)
Hualien Tzu Chi Hospital, Hualien City, Taiwan 970 Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan Taiwan
Taichung Veterans General Hospital, Taichung, Taiwan 407219 Taiwan
National Cheng Kung University Hospital, Tainan, Taiwan 704 Taiwan
National Taiwan University Hospital, Taipei, Taiwan 100225 Taiwan
Taipei Veterans General Hospital, Taipei, Taiwan 11217 Taiwan
Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan Taiwan
Kaohsiung Veterans General Hospital, Kaohsiung City, 813 Taiwan
MacKay Memorial Hospital, Taipei, 104 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. A clinical diagnosis of PH-ILD. 2. Subject voluntarily gives informed consent. 3. Subjects aged between 18 and 85 years at the time of signing informed consent. 4. Subjects must agree to practice protocol-defined birth control during the study period. * Males with a partner of childbearing potential must practice protocol-defined birth control for the duration of treatment and at least 96 hours after discontinuing the IP. * Female subjects of childbearing of potential (including those \<1-year post menopausal) must practice protocol-defined birth control during the conduct of the study and for 30 days after the last dose of IP (males only during exposure to IP). * Women not of childbearing potential are defined as: 1. Post-menopausal women (at least 12 months with no menses without an alternative medical cause); in women \<45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR 2. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR 3. Have a congenital or acquired condition that prevents childbearing. 5. The subject has a confirmed diagnosis of any form of interstitial lung disease based on high resolution computed tomography (HRCT) of the chest within 180 days prior to screening or at screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy). The subject can have other findings (e.g., emphysema) if this is not the predominant feature on the scan. 6. Subjects have undergone RHC during the screening period with the following documented parameters: * Pulmonary vascular resistance (PVR) ≥4 Wood units and * Pulmonary capillary wedge pressure (PCWP) of ≤12 mmHg \[if PVR ≥4 Wood units to \<6.25 Wood units\] or PCWP ≤15 mmHg \[if PVR ≥6.25 Wood units\] (a left ventricular end diastolic pressure \[LVEDP\] will be acceptable if a reliable PCWP cannot be obtained) and * A mean pulmonary arterial pressure (PAP) of \>20 mmHg. 7. Subjects must have a baseline 6-minute walk distance ≥100 meters and ≤500 meters. 8. Subjects agree to a repeat RHC, Chest CT, and MRI prior to study completion. 9. Subjects on chronic treatment for underlying lung disease (i.e., nintedanib or pirfenidone or immunosuppressive agents etc.) must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days. 10. Subjects on supportive medications (e.g., inhalers for asthma) must be on stable doses for ≥30 days prior to screening. 11. In the Investigator's opinion, the subject must be able to consent for themselves and communicate with local staff using interpreters if necessary. Subjects must agree to attend all study visits and be contactable through a cellular device or landline. 12. Subjects must have clinical laboratory values within normal ranges or \<1.5 times the upper limit of normal (ULN) as specified by the testing laboratory. 13. Pulmonary function test (PFT) showing a percent predicted forced vital capacity (FVC) \<70% of predicted and diffusion capacity of carbon monoxide (DLCO) \<70% corrected for hemoglobin (Hb) value ≥25% and ≤90% at screening (DLCO determined locally must be \<70%) using the American Thoracic Society (ATS) standards. 14. Subjects with a prior diagnosis of connective tissue diseases, specifically systemic sclerosis (scleroderma), systemic lupus erythematosus, Sjogren's disease, polymyositis/dermatomyositis/antisynthetase syndrome, rheumatoid arthritis can be included in the study, but no more than 20% of total subjects. 15. Negative serology test for hepatitis B surface antigen and hepatitis C antibody at Screening Visit. Exclusion Criteria: Medical Conditions 1. Subject has another concomitant diagnosis of pulmonary hypertension not otherwise considered to be PH-ILD. This would include and is not limited to the concomitant presence of thromboembolic disease, untreated/inadequately treated obstructive sleep apnea, human immunodeficiency virus (HIV), methamphetamine or anorexigenic drug use, and other conditions of the WHO Group 1, 2, 4, and 5 classifications. 2. Subject has evidence of clinically significant left-sided heart disease within 6 months as defined by: * Left ventricular ejection fraction \<40% as assessed by echocardiography. * More than mild left-sided valvulopathy (e.g., worse than mild mitral stenosis or regurgitation and worse than mild aortic stenosis or regurgitation). * LVEDP or PCWP \>15 mmHg (or \>12 mmHg if PVR ≥4 to 6.25 Wood units). 3. Subjects must NOT have 3 or more of the following left ventricular disease/dysfunction risk factors at screening: * Body mass index (BMI) ≥30 kg/m2. * Uncontrolled diabetes, HbA1C \>9.5%, urine glycosuria \>1.0 g/dl, or presence of diabetic ketoacidosis * History of significant coronary disease within 6 months of screening as demonstrated by any of the following: 1. History of myocardial infarction or acute coronary syndrome (unstable angina), or 2. Percutaneous coronary intervention or percutaneous transluminal angioplasty, or previous coronary artery bypass graft, or 3. Evidence of coronary artery disease (\>50% stenosis in at least one major coronary artery) or abnormal nuclear stress test. 4. The subject is receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest. 5. The subject has received any PH-approved therapy, including phosphodiesterase type 5 inhibitor, soluble guanylate cyclase inhibitor, endothelin receptor antagonist, or parenteral or oral prostacyclin therapy (excluding vasoreactivity testing) within 60 days of randomization or 5 half-lives. Inhaled prostacyclin (e.g., inhaled treprostinil) on stable doses for ≥30 days prior to screening will be allowed irrespective of local approval (as per ESC/ERS 2022). 6. Use of any potent inhibitors and potent inducers of cytochrome P450 3A4 (CYP3A4) (e.g., boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib, nefazodone, nelfinavir, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort). 7. Recent exacerbation of underlying lung disease or active pulmonary/upper respiratory tract infection within 4 weeks of randomization. 8. Any current active malignancy (this does not include localized cancers such as basal or squamous cell carcinoma of the skin). Any history of malignancy that is likely to result in mortality or require significant medical or surgical intervention within the following year. 9. Chronic kidney disease Stage IV or greater (i.e., eGFR ˂30 mL/min/1.73m2) or evidence of acute kidney injury. 10. The subject has a history of congenital heart disease irrespective of any prior treatment of surgical intervention 11. Use of tobacco, e-cigarette, nicotine, or marijuana products or significant history of drug or alcohol abuse within 6 months of screening. 12. Acute pulmonary embolism within 90 days of screening. 13. Participation in pulmonary rehabilitation within 90 days of screening. 14. Prior or concurrent use of any investigation drug/device/therapy or participation in any investigational study with therapeutic intent within 30 days or 5 half-lives, whichever is longer before the first dose of the IP. 15. BMI ≥40 kg/m2. 16. Uncontrolled hypertension as evidenced by systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg during the screening period. Subjects who fail screening due to high blo
Glaucoma Screening Using Artificial Intelligence Assisted Clinical Model in Singapore's Diabetic Eye Screening Program
NCT07243665
Recruiting
Conditions Glaucoma
Phase NA
Enrollment 1040
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is major cause of irreversible blindness and is characterized by optic nerve damage and visual field loss. Screening for glaucoma is challenging due to lack of a simple, accurate, cost-efficient and standardized process. Artificial intelligence, (AI) especially deep learning (DL) algorithms have potential to automate glaucoma detection, but have to be evaluated in real world settings, before public deployment. This study aims to evaluate the screening accuracy of a DL algorithm for glaucoma detection using colour fundus photographs (CFP) in a pragmatic randomised control trial (RCT). The algorithm will be tested in 1040 eligible patients with diabetes, recruited from the Diabetes \& Metabolism Centre's clinics under the Singapore Integrated Diabetic Retinopathy Program (SiDRP) and randomized to 2 arms: AI-assisted model vs current standard of care (grader assessment). The performance of both arms will be compared to performance of study ophthalmologist in diagnosing glaucoma. We hypothesize that the DL model has better screening performance in detecting glaucoma in the community, compared to the current practice method.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Single

Interventions / Regimen

  • Diagnostic Test: Artificial Intelligence model to detect glaucoma — A Vision Transformer model to detect glaucoma from fundus photos
  • Other: No intervention — Control group with current practice model by human graders

Primary Outcomes

  • Evaluation of model performance (At study completion (after all fundus images have been graded and data collection is finalized; approximately within 12 months of study initiation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-17
Completion: 2027-03
Eligibility
Age: 21 Years
Sex: ALL
Volunteers: false
Enrollment: 1040 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Singapore Eye Research Institute
Collaborators: Singapore General Hospital, SingHealth Polyclinics
Principal Investigators:
  • Ching-Yu Cheng, MD, PhD (PRINCIPAL_INVESTIGATOR) - Singapore Eye Research Institute
Contact Information
Study Contact:
Ching-Yu Cheng, MD, PhD
65767277
chingyu.cheng@duke-nus.edu.sg
Lavanya Raghavan, MD
65767201
raghavan.lavanya@seri.com.sg
Interventions
  • Diagnostic Test: Artificial Intelligence model to detect glaucoma — A Vision Transformer model to detect glaucoma from fundus photos
  • Other: No intervention — Control group with current practice model by human graders
Study Locations (1 sites)
Singapore National Eye Centre, Singapore, Singapore 168751 Singapore
Eligibility Criteria
Inclusion Criteria: We aim to recruit all eligible patients who attend Singapore General Hospital (SGH) Diabetes \& Metabolism Centre's (DMC) clinics and SingHealth Polyclinics (SHP)-Bukit Merah under the Singapore Integrated Diabetic Retinopathy Programme (SiDRP). Patients are eligible for the study if 1. Aged 21 years old and above, with diabetes, including type 1 and type 2, 2. Retinal photos of the patients can be taken with the fundus camera in the clinics, regardless of photos' quality, and 3. They are willing and capable of providing a written informed consent form. Exclusion Criteria: Patients meeting any of the exclusion criteria will be excluded from participation: 1. Patients who have difficulty in having retinal photos taken or have difficulties in completing the ocular examination protocols according to investigator's decision. 2. Any other contraindication(s) as indicated by the endocrinologists responsible for the patients. \-
Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis
NCT06122753
Not yet recruiting
Conditions Portal Hypertension, Portal Vein Thrombo...
Phase NA
Enrollment 120
Locations 1 sites
Compensation compensation available
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive TIPS is still controversial. The present study is directed at comparing the outcome of patients with acute variceal bleeding with occlusive PVT treated by standard therapy (vasoactive drugs + endoscopic variceal ligation) with or without preemptive TIPS (performed during the first 1-3 days after endoscopic procedure). The primary outcome is survival free of variceal rebleeding at 6 weeks from inclusion.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: preemptive TIPS — The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
  • Procedure: standard second prophylaxis — Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg. The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.

Primary Outcomes

  • 6-week mortality (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2024-01
Completion: 2026-12
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West China Hospital
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Beijing YouAn Hospital, Beijing Friendship Hospital, Beijing 302 Hospital
Principal Investigators:
  • Xuefeng Luo, Ph.D. (PRINCIPAL_INVESTIGATOR) - West China Hospital
Contact Information
Study Contact:
Xiazoe Wang, M.D.
+8615208207573
wang_xiaoze@wchscu.cn
Interventions
  • Procedure: preemptive TIPS — The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
  • Procedure: standard second prophylaxis — Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg. The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.
Study Locations (1 sites)
West China Hospital of Sichuan University, Chengdu, Sichuan 610000 China
Eligibility Criteria
Inclusion Criteria: * Cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy); * Admission due to acute bleeding from esophagogastric varices; * Thrombus in the main trunk of the portal vein occupying ≥50% of the lumen. Exclusion Criteria: * Prior treatment with TIPS or surgical shunt; * Presence of contraindications to endoscopic treatment, carvedilol, or TIPS; * Presence of hepatocellular carcinoma exceeding Milan criteria; * Presence of other systemic malignant tumors with expected survival time not exceeding 6 months; * Presence of uncontrollable infection or sepsis; * Presence of cardiac, pulmonary, or renal failure; * Pregnant or lactating women; * Refusal to sign the informed consent form.
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162
Not yet recruiting
Conditions Hypertension, Hypercortisolemia, Cushing...
Phase PHASE4
Enrollment 63
Locations 0 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Osilodrostat — Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.
  • Drug: Placebo — matching placebo

Primary Outcomes

  • To evaluate the efficacy of osilodrostat on the proportion of participants with normalisation of urinary-free cortisol (UFC) (30 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Not yet recruiting
Start Date: 2026-08
Completion: 2028-07
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 63 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RECORDATI GROUP
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Drug: Osilodrostat — Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.
  • Drug: Placebo — matching placebo
Eligibility Criteria
Inclusion Criteria: 1. Male or female ≥ 18 years of age 2. Able to provide and have provided signed written informed consent prior to study participation 3. Diagnosis of endogenous Cushing's Syndrome 4. mUFC values from two 24h urinary collections \> ULN and ≤ 2x ULN 5. Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg 6. Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer 7. Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments: 1. Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week 2. Mifepristone: 3 weeks 3. SC Pasireotide: 1 week 4. Pasireotide LAR: 3 months 5. Cabergoline: 4 weeks 8. Able to take oral medication and be willing to comply with the requirements of the study Exclusion Criteria: 1. Previously treated with osilodrostat less than 12 weeks prior to start of screening 2. Known hypersensitivity to osilodrostat 3. Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study 4. Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug 5. Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed \>10 years prior to the initial diagnosis of endogenous CS) 6. History of cyclic Cushing's Syndrome with fluctuating clinical manifestations 7. Participants with pseudo-CS 8. Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm) 9. Pituitary radiation therapy within 3 years of screening 10. Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of \<3 years or receiving chemotherapy 11. Having received prior mitotane treatment 12. Participants who are shift workers or have conditions that can affect the measurement of late night salivary cortisol (LNSC) or the LDDST 13. Poorly controlled diabetes mellitus with a baseline HbA1c \> 10.5% 14. Poorly controlled BP defined as: Average SBP ≥ 170 or average DBP ≥ 110 mmHg as measured by the 24h ABPM 15. Participants who are hypothyroid and not on adequate replacement therapy 16. History of major surgery/surgical therapy for any cause within 1 month before entering the study. 17. Presence of bradycardia and/or QT-related exclusion criteria 18. Total bilirubin \> 1.5 x ULN and ALT or AST \> 3 x ULN 19. Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 1 month prior to dosing) 20. Occurrence of any significant acute illness within the three weeks prior to dosing/randomisation 21. Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test 22. Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods 23. Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study
Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan
NCT06852079
Recruiting
Conditions Hypertension
Phase PHASE3
Enrollment 119
Locations 1 sites
Compensation Phase 3: Typically $200-$1,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Qurs e Fishar — Qurs e Fishar is a herbal remedy for Hypertension

Primary Outcomes

  • Blood Pressure (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-12-23
Completion: 2025-12-31
Eligibility
Age: 30 Years
Sex: ALL
Volunteers: false
Enrollment: 119 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abdul Bari
Collaborators: Hamdard University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Other: Qurs e Fishar — Qurs e Fishar is a herbal remedy for Hypertension
Study Locations (1 sites)
Taj Medical Complex, Hamdard University Hospital, Karachi, Sindh Pakistan
Eligibility Criteria
Inclusion Criteria: * Ability to sign ICD * Participant(s) are willing and able to fulfill the requirements of the study protocol * Mild to moderate hypertensive * Mild hypertension range (140-159/90-99 mm Hg) * Moderate hypertension range (160-179/100-109 mm Hg) * Be between the age of 30 to 60 year Exclusion Criteria: * Patients with recent history of following will be excluded: * Severe hypertension, * Congestive cardiac failure, * Left ventricular failure, * Myocardial ischemia, * Renal failure or * Cerebrovascular accidents
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
NCT06760169
Recruiting
Conditions Glaucoma
Phase NA
Enrollment 46
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Surgery with ELIOS laser — This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.

Primary Outcomes

  • Intraocular pressure (IOP) (day 0, 7 and 30, and month 3, 6 and 12 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-05
Completion: 2028-02-28
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hôpital Privé de la Baie
Contact Information
Study Contact:
Ana Miguel, MD
+33787016187
myworld_ana@hotmail.com
Interventions
  • Device: Surgery with ELIOS laser — This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.
Study Locations (1 sites)
Hôpital Privé de la Baie, Avranches, 50300 France
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years of age who agree to take part in the study and have signed an informed consent form * Visually significant cataract with indication for surgery * Primary open-angle glaucoma, or secondary open-angle glaucoma (pseudoexfoliative glaucoma or pigmentary glaucoma) with indication for cataract surgery. * Open iridocorneal angle (Shaffer classification grade 2-4) * Early to moderate glaucoma (advanced glaucoma, with MD from VFs worse than -12dB, will be excluded) Exclusion Criteria: * Presence of severe systemic pathologies 2024-A01891-46\_Protocol\_V6\_21112024\_Elios Page 20 / 58 * Pregnant or breastfeeding women * \<18 years of age * Presence of other ophthalmological pathologies (except cataracts), and exclusion of severe dry eye. * History of intraocular surgery, trauma, or conjunctival scarring in the quadrant intended for surgery * Visual acuity worse than "counting fingers". * Closure of the iridocorneal angle (and angle-closure glaucoma), angle-closure glaucoma secondary to iridocorneal synechiae, neovascular glaucoma or neovascularization of the iris. * Normal-pressure glaucoma * Pachymetry \< 490 um or \> 620 μm * Glaucomatous visual field with mean deviation worse than ≤-12 dB * IOP \> 35 mmHg * Autoimmune disorder, especially collagenosis * Patient under protective supervision * Patient not covered by a social security scheme
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
NCT02726711
Active, positions filled
Conditions Multiple System Atrophy, Orthostatic Hyp...
Phase PHASE1
Enrollment 2
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn more about the regulation of the veins of the abdomen by the autonomic (involuntary) nervous system, and how this may affect high blood pressure. Normally, the autonomic nervous system controls how much blood flows in the veins. In people with high blood pressure, however, the autonomic nervous system is changed. This change may affect the way blood flows in the veins of the abdomen which may play a role in their high blood pressure. About 32 participants will be screened for the study. The investigators estimate 16 will be eligible to participate in all of the study days.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Drug: Trimethaphan — Trimethaphan will be infused (0.5 - 4.0 mg IV)
  • Drug: Placebo — 0.5 - 4.0 mg IV to be infused

Primary Outcomes

  • The percentage of increase of the y intercept of the P-V relationship (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Active, positions filled
Start Date: 2016-04
Completion: 2026-12
Eligibility
Age: 40 Years
Sex: ALL
Volunteers: false
Enrollment: 2 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University
Principal Investigators:
  • Italo Biaggioni, M.D. (PRINCIPAL_INVESTIGATOR) - Vanderbilt University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Drug: Trimethaphan — Trimethaphan will be infused (0.5 - 4.0 mg IV)
  • Drug: Placebo — 0.5 - 4.0 mg IV to be infused
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Male and female subjects, age 40-80 years, with possible or probable Multiple System Atrophy, as defined by Consensus Criteria. * Neurogenic orthostatic hypotension defined as a ≥30-mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes. * Supine hypertension, defined as systolic blood pressure ≥150 mmHg measured on two separate occasions. * Subjects able and willing to provide informed consent. Exclusion Criteria: * Pregnancy. * Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies * History of known aortic aneurysms, thoracic, abdominal or pelvic surgery in the past 6 months * Symptomatic abdominal or inguinal hernias * Severe gastroesophageal reflux * Recent fractures or fissures of ribs, thoracic or lumbar spine * Medical devices implanted on the abdominal wall or abdomen that would interfere with the abdominal compression * Intolerance to any increase in intra-abdominal pressure * Clinically unstable coronary artery disease or major cardiovascular or neurological event in the past 6 months, and other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing.
The Jiaxing Birth Cohort in China
NCT03217656
Recruiting
Conditions Childhood Obesity, Anemia, Pregnancy Com...
Phase Not Applicable
Enrollment 500000
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The Jiaxing Birth Cohort (JBC) is the largest prospective cohort study to explore prenatal risk factors, early life feeding practice and growth pattern/ adiposity in Chinese children.Between 1999 and 2013, 338 413 mother-child pairs were recruited in Jiaxing area in south-east China.Children of the recruited women were followed up at 1-2, 3, 6, 9 and 12 months of age, and subsequently followed up every 6 months to 36 months of age (toddler stage), and every year to 6-7 years of age before they went to school (pre-school stage). Follow-up rate was 70.8% at the toddler stage and 68.9% at the pre-school stage up to June 2013.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention

Primary Outcomes

  • overweight and obesity (Up to 6-7 years old for these children)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 1999-01
Completion: 2029-01
Eligibility
Age: No restriction
Sex: ALL
Volunteers: true
Enrollment: 500000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang University
Collaborators: Jiaxing Maternity and Child Health Care Hospital, Qingdao University, Westlake University
Contact Information
Study Contact:
Duo Li, PhD
duoli@zju.edu.cn
Ju-Sheng Zheng, PhD
zhengjusheng@wias.org.cn
Interventions
  • Other: No intervention
Study Locations (1 sites)
Zhejiang University, Hangzhou, Zhejiang 310058 China
Eligibility Criteria
Inclusion Criteria: 1. Pregnant women came to clinic visit at one of the local hospitals during pregnancy at Jiaxing area 2. Pregnant women were followed up during pregnancy and their children were born alive at local hospital or clinics Exclusion Criteria: 1. Those who did not want to participant 2. The infant was dead at the birth 3. Those pregnant mothers who dropped out during follow-up at pregnancy or moved out of the Jiaxing area